Comparison of infusion or low-dose proton pump inhibitor treatments in upper gastrointestinal system bleeding
| Autor: | Yıldıran Songür, Ayşe Balkarli, Altug Senol, Gursel Acarturk |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Peptic Ulcer medicine.medical_specialty medicine.drug_class Proton-pump inhibitor Esomeprazole Upper Gastrointestinal Tract Bolus (medicine) Infusion therapy Recurrence Internal Medicine medicine Clinical endpoint Humans Blood Transfusion Prospective Studies Infusions Intravenous Prospective cohort study Aged Dose-Response Relationship Drug business.industry Mortality rate Hemostasis Endoscopic Proton Pump Inhibitors Length of Stay Middle Aged Surgery Hospitalization Anesthesia Hemostasis Female Gastrointestinal Hemorrhage business Vascular Surgical Procedures medicine.drug |
| Zdroj: | European Journal of Internal Medicine. 22:200-204 |
| ISSN: | 0953-6205 |
| DOI: | 10.1016/j.ejim.2010.11.007 |
| Popis: | Background The most effective schedule of proton pump inhibitor (PPI) administration following endoscopic hemostasis of bleeding ulcers remains uncertain. Aim To compare the treatment effects of continuous infusion and low-dose esomeprazole therapies in patients with non-variceal upper gastrointestinal (GI) bleeding. Methods This prospective clinical study compared continuous infusion of esomeprazole (80 mg bolus followed by 8 mg∕h continuous infusion for 72 h) and low-dose esomeprazole (40 mg twice daily IV) treatments in GI bleeding patients with peptic ulcer presenting a high risk of re-bleeding, who were administered a successful endoscopic homeostasis. The primary end point was the occurrence of re-bleeding during hospitalization and within one month of discharge. Secondary outcomes were defined as duration of hospitalization, need of transfusion, surgical treatment, and mortality rate. After 72 h, both groups were switched to oral esomeprazole therapy for one-month. Results A hundred thirty-two subjects were enrolled. Re-bleeding occurred in 11 (16.7%) patients in the infusion therapy group and in 12 (18.2%) patients in the low-dose group (P = 0.819) within the first 72 h. No patient experienced re-bleeding in the first month following discharge. There was no statistical significant difference between the two groups in terms of transfusion need, durations of hospitalization, need for surgery and mortality rate. Conclusion PPI infusion therapy following endoscopic hemostasis treatment was not found superior to low-dose PPI therapy in the terms of re-bleeding, need of surgery and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect